康圣环球品牌怎么样 申请店铺

更新时间:2023-03-31
康圣环球是哪个国家的品牌?「康圣环球」是康圣环球(北京)医学技术有限公司旗下著名品牌。该品牌发源于北京/海淀区,由创始人黄士昂在2007-11-20期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
康圣环球怎么样

康圣环球医学特检集团(以下简称“康圣环球”)是中国首家和最大高端医学专科特检服务检验集团。康圣环球致力于引领中国专科特检技术和服务的进步,以促进中国专科诊疗和个性化医学的发展和提高。本着病人利益至上、医生需求第一的宗旨,康圣环球遵循国际规范、标准和行业指南,引进和研发世界上最先进的技术和专科特检方法,面向中国大型三级医院、专科医院和综合性医院提供全面、先进和准确的专科特检服务。集团创业和管理团队核心成员均在美国学术和产业界工作十年以上,视野广阔,经验丰富。集团得到了世界上最著名和最大的创投基金凯鹏华盈(KPCB)、晨兴创投、中经合、贝雅等几千万美元的资本支持。并在2011年6月27日,美国梅奥医学中心(MayoClinic)宣布与中国康圣环球医学特检集团正式签署一项长达数年的战略合作协议,梅奥向康圣环球注资,通过其医学检验与病理学部及其旗下的梅奥医学实验室,为康圣环球提供近3000项专业检测技术及实验室质量管理,国际认证标准、信息咨询、标准操作程序(SOPs)和方法学等相关技术,协助康圣环球加速发展其在中国的高品质特检服务,促进中国医学诊断和治疗水平的提高。

康圣环球在北京、上海、武汉已建和在建三万八千平方米具有国际先进水平的、具有国家资质的临床检验、科研合作和应用开发中心,拥有高分辨流式细胞仪、多色流式细胞分选与细胞培养、多色荧光适时幼态细胞扫描成像仪、第二代基因组学测序、基因芯片、全自动DNA/RNA提取、COBAS高灵敏度病毒载量系统、高精度质谱、质谱芯片、高压液相/气相层析、分子细胞、遗传与全自动核型扫描、变性高效色谱分析、分子病理、数字病理、液态芯片、单分子数字免疫、免疫组化、蛋白指纹图谱、激光共聚焦显微镜、电子显微镜等数十个技术平台和专业实验室,向全国三十一个省直辖市,六百多个城市的三千多家医院,尤其是千余家大型三级医院提供三千多项血液、肿瘤、遗传、心脑血管、感染性疾病、自身免疫性疾病等领域和内、外、妇、儿等专科的高精尖诊断检测,并通过与全球顶尖医疗科技机构和大型制药公司合作,向全国广大临床医师提供医学科研、药物试验和转化医学研究服务。


Kangsheng global medical special examination group (hereinafter referred to as "Kangsheng global") is the first and largest high-end medical special examination service inspection group in China. Kangsheng global is committed to leading the progress of special examination technology and services in China, so as to promote the development and improvement of specialized diagnosis and treatment and personalized medicine in China. In line with the tenet of putting patients' interests first and doctors' needs first, Kangsheng universal follows international norms, standards and industry guidelines, introduces and develops the most advanced technology and special examination methods in the world, and provides comprehensive, advanced and accurate special examination services for large-scale tertiary hospitals, specialized hospitals and general hospitals in China. The core members of the group's entrepreneurship and management team have worked in the academic and industrial circles of the United States for more than ten years, with broad vision and rich experience. The group has received capital support of tens of millions of US dollars from KPCB, Chenxing venture capital, China economic cooperation and paya, the world's most famous and largest venture capital fund. And on June 27, 2011, Mayoclinic of the United States announced that it has signed a strategic cooperation agreement with China global medical special inspection group for several years. Mayo has invested in global health. Through its Department of medical testing and pathology and its Mayo Medical Laboratory, it has provided global health with nearly 3000 professional testing technologies and laboratory quality management, international certification standards and information Consulting, SOPs, methodology and other related technologies will help Corson global to accelerate the development of its high-quality special examination services in China and promote the improvement of medical diagnosis and treatment level in China. Kangsheng global has established and is in the process of building 38000 square meters of clinical testing, scientific research cooperation and application development center with international advanced level and national qualification in Beijing, Shanghai and Wuhan. It has high-resolution flow cytometry, multi-color flow cell sorting and cell culture, multi-color fluorescence real-time young cell scanning imager, second-generation genomics sequencing, gene chip, and full-scale fluorescence Automatic DNA / RNA extraction, Cobas high-sensitivity viral load system, high-precision mass spectrometry, mass spectrometry chip, high-pressure liquid / gas chromatography, molecular cell, genetic and full-automatic nuclear scanning, denaturing high-performance chromatography, molecular pathology, digital pathology, liquid chip, single molecule digital immune, immunohistochemistry, protein fingerprint, laser confocal microscope, electron microscope, etc Ten technical platforms and professional laboratories provide more than 3000 hospitals in 31 provinces, municipalities directly under the central government and more than 600 cities in China, especially more than 1000 large tertiary hospitals, with more than 3000 high-end diagnostic tests in the fields of blood, tumor, genetics, cardio cerebrovascular, infectious diseases, autoimmune diseases, and in the fields of internal, external, women, children and other specialties, and have passed the world's top doctors Medical science and technology institutions and large pharmaceutical companies cooperate to provide medical research, drug testing and translational medical research services to clinicians across the country.

本文链接: https://brand.waitui.com/b8bc6d5cc.html 联系电话:18500087003

7×24h 快讯

RoboSense与上汽集团进入规模化量产合作新阶段

36氪获悉,RoboSense速腾聚创正式公布与上汽集团旗下汽车品牌飞凡汽车的定点合作。日前,双方合作的车型之一飞凡F7正式上市交付。这标志着,RoboSense速腾聚创与上汽集团的量产车型定点合作全面进入了规模化量产的新阶段。

2小时前

热门中概股美股盘前多数上涨,京东涨超5%

36氪获悉,热门中概股美股盘前多数上涨,截至发稿,京东涨超5%,拟分拆京东产发、京东工业于香港联交所主板独立上市;微博涨超3%,拼多多、蔚来、小鹏汽车、爱奇艺涨超1%,B站涨0.49%,理想汽车涨0.24%,百度跌超2%。

2小时前

贵州茅台:2022年净利润627.16亿元,同比增长19.55%

36氪获悉,贵州茅台发布年报,2022年营业收入1240.99亿元,同比增长16.87%;净利润627.16亿元,同比增长19.55%;基本每股收益49.93元。拟10派259.11元。

2小时前

天齐锂业:2022年净利润241.25亿元,同比增长1060.47%

36氪获悉,天齐锂业发布年报,2022年营业收入404.48亿元,同比增长427.82%;净利润241.24亿元,同比增长1060.47%,拟10派30元。

2小时前

亚朵集团上市后首份成绩单:2022年调整后净利润同比增85.6%至2.59亿元

亚朵集团发布2022年第四季度及全年业绩报告。2022年,亚朵集团实现营收22.63亿元,同比增长5.4%;调整后净利润(非公认会计准则)为2.59亿元,同比增长85.6%。截至2022年12月31日,亚朵集团现金及现金等价物为15.89亿元。报告期内,亚朵新开店191家,仅4家关店,在营酒店数量达932家,房间数达10.8万间,均较上年增长25%;场景零售业务增长迅猛,GMV同比增长42%至3.24亿元。

2小时前

本页详细列出关于康圣环球的品牌信息,含品牌所属公司介绍,康圣环球所处行业的品牌地位及优势。
咨询